We discovered experimental agents, including MEK inhibitors PD19830 and BRD-K12244279, pilocarpine, and tremorine as potential new drug options for improving breast cancer survival outcomes, which were previously unknown. This evidence concerns the gene MAP2K7 and breast cancer.